As we first reported in the April 18, 2008 issue of GC News, although number of studies have shown that herpes simplex virus type 2 (HSV-2) infection is associated with an increased likelihood of acquiring HIV, treating people who have HSV-2 doesn’t reduce their risk of HIV infection. In the June 21st issue of the Lancet, Dr. Connie Celum and her colleagues at the University of Washington present the results from the second large-scale clinical trial designed to test whether treating HSV-2 can help prevent HIV infection among high-risk individuals. They found no evidence of a protective effect.

In the accompanying editorial, Drs. Ronald Gray and Maria Wawer of Johns Hopkins University argue that these findings call into question current prevention policies that focus on control of sexually transmitted diseases to lower transmission of HIV, stating: “It is time to reassess [this] hypothesis and to adjust prevention policy accordingly.”